Advancing Immunotherapy Research

With the growing importance of immune checkpoint inhibitors in cancer therapy, our anti-CTLA-4 antibodies provide researchers with a powerful tool to explore the therapeutic potential and mechanisms of immune modulation.

Whether for understanding CTLA-4's role in immune tolerance or developing next-generation immunotherapies, our product supports cutting-edge research in immuno-oncology.

Anti-CTLA4 Antibodies

View as Grid List

8 Items

per page
Set Descending Direction
  1. Ipilimumab Biosimilar - Research Grade
    $120.00 - $5,000.00
  2. Ipilimumab Biosimilar - Biotin Research Grade
    $350.00
  3. Ipilimumab Biosimilar - HRP Research Grade
    $350.00
  4. Anti-Mouse CTLA-4 (9D9) In Vivo Antibody - Low Endotoxin
    $370.00 - $3,630.00
  5. Vudalimab Biosimilar - Research Grade
    $350.00 - $9,000.00
  6. Anti-CTLA-4 (9H10) In Vivo Antibody - Low Endotoxin
    $370.00 - $3,630.00
  7. Tremelimumab Biosimilar - Research Grade
    $300.00 - $5,000.00
  8. Anti-Mouse CTLA-4 (UC10-4F10-11) In Vivo Antibody - Low Endotoxin
    $380.00 - $3,630.00
View as Grid List

8 Items

per page
Set Descending Direction

The Role of Anti-CTLA-4 Antibodies in Research and Immunotherapy

Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), also known as CD152, is a critical immune checkpoint receptor expressed on the surface of T cells. It plays a pivotal role in regulating the immune system by downregulating T-cell activation, promoting immune tolerance, and preventing autoimmunity. CTLA-4 competes with the costimulatory receptor CD28 for binding to B7 ligands (CD80 and CD86) on antigen-presenting cells, inhibiting T-cell proliferation and reducing immune responses.

Anti-CTLA-4 antibodies are invaluable tools in immunological research and cancer immunotherapy. By blocking the interaction between CTLA-4 and its ligands, these antibodies can enhance T cell activation and proliferation, leading to a stronger immune response against tumors.

Product Highlights Specificity: Our Anti-CTLA-4 antibodies are developed to target the CTLA-4 receptor with high specificity, making it ideal for studying immune regulation and the CTLA-4 pathway in cancer immunotherapy research.

Isotype: We manufacture mouse, hamster and human isotype controls, mirroring the isotype of our best-selling anti-CTLA-4 antibodies to provide a relevant model for immunotherapy research.

Conjugation: Available as an unconjugated antibody, with custom conjugation services to fit specific research needs. Applications: Functional assays, blocking experiments, and flow cytometry analysis to investigate CTLA-4 signaling and its blockade's effects on T cell activation and tumor immunity.

Formulation: Phosphate-buffered saline (PBS), pH 7.4, without stabilizers or preservatives, ensuring stability and biological activity.

Purity: >95% purity confirmed by SDS-PAGE, suitable for various research applications.

Production and Purification: Produced in an animal-free facility and purified by affinity chromatography to ensure high quality and reproducibility.

Sterility and Safety: Filtered at 0.2 μm and rigorously tested for pathogens to ensure research safety and reliability. Anti-mouse CTLA-4 antibodies

Top clones include 9D9, 9H10 and UC10-4F10-11

Anti-human CTLA-4 antibodies

Top biosimilars include Ipilimumab & Tremelimumab

CTLA-4 Fusion Proteins

Abatacept, Belatacept

Considerations for Use

  • Anti-CTLA-4 antibodies are for research use only and not for therapeutic or diagnostic applications.
  • We recommend using our provided isotype control and dilution buffers for optimal results.
Back to Top